Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
2.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

3.

Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.

Kunath F, Goebell PJ, Wullich B, Sikic D, Kahlmeyer A.

World J Urol. 2019 Mar 4. doi: 10.1007/s00345-019-02704-y. [Epub ahead of print]

PMID:
30830274
4.

Piwi-like 1 and -2 protein expression levels are prognostic factors for muscle invasive urothelial bladder cancer patients.

Eckstein M, Jung R, Weigelt K, Sikic D, Stöhr R, Geppert C, Agaimy A, Lieb V, Hartmann A, Wullich B, Wach S, Taubert H.

Sci Rep. 2018 Dec 6;8(1):17693. doi: 10.1038/s41598-018-35637-4.

5.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
6.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

PMID:
30483954
7.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

8.

FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer.

Breyer J, Wirtz RM, Erben P, Rinaldetti S, Worst TS, Stoehr R, Eckstein M, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W.

BJU Int. 2019 Jan;123(1):187-196. doi: 10.1111/bju.14525. Epub 2018 Sep 9.

PMID:
30120861
9.

Evolution of PD-1 and PD-L1 Gene and Protein Expression in Primary Tumors and Corresponding Liver Metastases of Metastatic Bladder Cancer.

Eckstein M, Sikic D, Strissel PL, Erlmeier F; BRIDGE Consortium Germany.

Eur Urol. 2018 Oct;74(4):527-529. doi: 10.1016/j.eururo.2018.06.028. Epub 2018 Jul 12. No abstract available.

PMID:
30007816
10.

High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.

Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W; Bladder Cancer Research Initiative for Drug Targets Germany (BRIDGE) Consortium eV, Mannheim, Germany.

Clin Genitourin Cancer. 2018 Aug;16(4):248-256.e2. doi: 10.1016/j.clgc.2018.01.009. Epub 2018 Feb 2.

PMID:
29525349
11.

Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis.

Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J; Bridge Consortium.

PLoS One. 2017 Jun 20;12(6):e0179602. doi: 10.1371/journal.pone.0179602. eCollection 2017.

12.

High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer.

Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stöhr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W.

Transl Oncol. 2017 Jun;10(3):340-345. doi: 10.1016/j.tranon.2017.01.013. Epub 2017 Mar 22.

13.

How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Lieb V, Krause FS, Merten R, Ott O, Fietkau R, Wullich B, Keck B.

Urol Int. 2017;98(3):262-267. doi: 10.1159/000447361. Epub 2016 Jul 5.

PMID:
27376673
14.

[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].

Lieb V, Rink M, Sikic D, Keck B.

Urologe A. 2016 Jun;55(6):805-12. doi: 10.1007/s00120-016-0090-9. German.

PMID:
27146873
15.

[Side effect management of tyrosine kinase inhibitors in urology : Hypertension].

Sikic D, Meidenbauer N, Lieb V, Keck B.

Urologe A. 2016 Jul;55(7):952-5. doi: 10.1007/s00120-016-0089-2. Review. German.

PMID:
27146871
16.

[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].

Sikic D, Lüdecke G, Lieb V, Keck B.

Urologe A. 2016 May;55(5):648-52. doi: 10.1007/s00120-016-0088-3. Review. German.

PMID:
27119958
17.

Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.

Kunath F, Borgmann H, Blümle A, Keck B, Wullich B, Schmucker C, Sikic D, Roelle C, Schmidt S, Wahba A, Meerpohl JJ.

BMJ Open. 2015 Nov 13;5(11):e008217. doi: 10.1136/bmjopen-2015-008217. Review.

18.

Female Gender Is an Age-dependent Negative Prognostic Factor for Patients with Upper Tract Urothelial Carcinoma.

Sikic D, Wach S, Taubert H, Richterstetter M, Kunath F, Goebell PJ, Schick S, Olbert P, Huber J, Wullich B, Keck B.

Anticancer Res. 2015 Jul;35(7):4277-81.

PMID:
26124390
19.

Risk stratification for locoregional recurrence after radical cystectomy for urothelial carcinoma of the bladder.

Novotny V, Froehner M, May M, Protzel C, Hergenröther K, Rink M, Chun FK, Fisch M, Roghmann F, Palisaar RJ, Noldus J, Gierth M, Fritsche HM, Burger M, Sikic D, Keck B, Wullich B, Nuhn P, Buchner A, Stief CG, Vallo S, Bartsch G, Haferkamp A, Bastian PJ, Hakenberg OW, Propping S, Aziz A.

World J Urol. 2015 Nov;33(11):1753-61. doi: 10.1007/s00345-015-1502-y. Epub 2015 Feb 8.

PMID:
25663359
20.

Fetal macrosomia--pregnancy and delivery.

Mikulandra F, Stojnić E, Perisa M, Merlak I, Sikić D, Zenić N.

Zentralbl Gynakol. 1993;115(12):553-61.

PMID:
8147169
21.

[Pregnancy, labor and the neonate in multiparas under 34 years of age].

Mikulandra F, Perisa M, Kimer M, Merlak I, Sikić D.

Srp Arh Celok Lek. 1991 Sep-Oct;119(9-10):235-7. Serbian.

PMID:
1806989
22.

[Pregnancy and labor in women over 40 years of age].

Mikulandra F, Merlak I, Perisa M, Sikić D, Jerković J.

Jugosl Ginekol Perinatol. 1991 Jan-Apr;31(1-2):11-5. Croatian.

PMID:
1875713
23.

[Perinatal outcome in older primiparas].

Mikulandra F, Perisa M, Merlak I, Stojnić E, Kimer M, Sikić D, Jerković J.

Jugosl Ginekol Perinatol. 1990 Sep-Dec;30(5-6):137-41. Croatian.

PMID:
2094795
24.

[Pregnancy, labor and the neonate in pluriparas and multiparas].

Mikulandra F, Perisa M, Merlak I, Kimer M, Sikić D, Jerković J.

Jugosl Ginekol Perinatol. 1990 May-Aug;30(3-4):83-6. Croatian.

PMID:
2273908
25.

[Chronic musculo-skeletal disorders in workers working with electrolytic extraction of aluminum].

Jurić M, Sikić D.

Arh Hig Rada Toksikol. 1986 Sep;37(3):347-51. Croatian. No abstract available.

PMID:
3619661
26.

[Relation between the time of treatment and the success of treatment in congenital hip dislocation].

Zaninović B, Stipanićev S, Jurić M, Sikić D.

Lijec Vjesn. 1985 Sep;107(9):392-5. Croatian. No abstract available.

PMID:
4046728
27.

[Intrauterine growth of live-born twins in the area of Sibenik, Split and Zadar].

Mikulandra F, Tadin I, Franceschi A, Sikić D, Skevin Z.

Jugosl Ginekol Opstet. 1983 May-Aug;23(3-4):88-92. Croatian.

PMID:
6664110

Supplemental Content

Support Center